Krebs H B, Myers M B, Wheelock J B, Goplerud D R
Cancer. 1985 Jun 1;55(11):2645-8. doi: 10.1002/1097-0142(19850601)55:11<2645::aid-cncr2820551119>3.0.co;2-j.
Twenty-seven consecutive patients with advanced gynecologic malignancies undergoing chemotherapy with cisplatin in combination with other agents were studied in a prospective, randomized fashion to compare the antiemetic efficacy of a combination regimen with high-dose metoclopramide. The combination regimen consisted of prochlorperazine, dexamethasone, and pentobarbital. Patients treated with the combination regimen had significantly less vomitus (P less than 0.01, Student's t test) and fewer vomiting episodes (P less than 0.001, test for homogeneity) than patients treated with metoclopramide. In addition, the sedative and sleep-inducing effect of the barbiturate made the experience of vomiting more tolerable, even in those instances where the combination regimen was not superior to metoclopramide in the control of vomiting.
对27例连续接受顺铂联合其他药物化疗的晚期妇科恶性肿瘤患者进行了一项前瞻性随机研究，以比较高剂量胃复安联合方案的止吐疗效。联合方案由丙氯拉嗪、地塞米松和戊巴比妥组成。与接受胃复安治疗的患者相比，接受联合方案治疗的患者呕吐物明显减少（P<0.01，Student t检验），呕吐发作次数更少（P<0.001，齐性检验）。此外，巴比妥类药物的镇静和诱导睡眠作用使呕吐体验更易于耐受，即使在联合方案控制呕吐方面并不优于胃复安的情况下也是如此。
